Evidence Hub

Response to Comments on ‘Smoking and Risk of Uveitis: A Systematic Review and Meta-Analysis‘

Marjolein Drent, Sanela Kuč, Roel J Erckens, Carroll A. B. Webers

Ocular immunology and inflammation, 2025

1 citation

Abstract

ABSTRACT In response to recent comments on our meta-analysis, we reaffirm that smoking is a major modifiable risk factor for uveitis, with consistent evidence demonstrating increased odds of disease across multiple anatomic subtypes. Biological plausibility is supported by mechanisms such as oxidative stress, endothelial dysfunction, and cytokine activation. Smoking also affects treatment response: current smokers with immune-mediated diseases such as psoriasis, Crohn’s disease, and rheumatoid arthritis show reduced likelihood of achieving remission or near-complete clearance after biologic therapy. Tobacco use contributes to systemic organ damage, including cardiovascular, pulmonary, and ocular complications such as macular edema. Heterogeneity in exposure assessment and limited e-cigarette data highlight the need for further research. Nevertheless, clinicians should actively counsel patients to stop smoking or vaping. Reducing modifiable risk factors may improve treatment efficacy, lower inflammation, and prevent recurrence. Ophthalmologists play a key role in prevention and optimizing outcomes in uveitis.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free